Pictet Asset Management
SWTX

Pictet Asset Management’s SpringWorks Therapeutics SWTX Stock Holding History

Pictet Asset Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,620
Closed -$452K – 2083
2025
Q2 		$452K Sell
9,620
-1,660,388
-99% -$73.9M ﹤0.01% 1402
2025
Q1 		$73.7M Sell
1,670,008
-721,404
-30% -$33.2M 0.08% 242
2024
Q4 		$86.4M Buy
2,391,412
+465,494
+24% +$16.3M 0.09% 224
2024
Q3 		$61.7M Buy
1,925,918
+306,076
+19% +$11.4M 0.07% 260
2024
Q2 		$61M Buy
1,619,842
+3,684
+0.2% +$155K 0.07% 251
2024
Q1 		$79.5M Buy
1,616,158
+57,671
+4% +$2.67M 0.09% 236
2023
Q4 		$56.9M Buy
1,558,487
+504,630
+48% +$13.2M 0.06% 278
2023
Q3 		$24.4M Buy
+1,053,857
New +$28.8M 0.03% 413

Other funds holding SWTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Pictet Asset Management's SWTX Position: Q3 2025 in Review

Pictet Asset Management sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 9,620 shares — an estimated $452K sold.

Pictet Asset Management first reported a position in SWTX in Q3 2023 and held it in 8 quarters. The position peaked at $86.4M in Q4 2024. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

  • Pictet Asset Management reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Pictet Asset Management sold 9,620 SpringWorks Therapeutics shares in Q3 2025, an estimated $452K.
  • Pictet Asset Management first reported a position in SpringWorks Therapeutics in Q3 2023 and held it in 8 quarters.
  • Pictet Asset Management's SpringWorks Therapeutics position peaked at $86.4M in Q4 2024.
  • 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Pictet Asset Management's 13F filing for Q3 2025, filed 18 Nov 2025.